Peter Arlett

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 9

Top Topics

Decision Making

Transcription Factor

Top Venues

Clinical pharmacology and therapeutics

British journal of clinical pharmacology

Pharmacoepidemiology and drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Stefanie Prilla, Sophie Groeneveld, Alexandra C Pacurariu, María Clara Restrepo-Méndez, Patrice Verpillat, Carla Torre, Christian Gartner, Peter G M Mol, Frauke Naumann-Winter, Kieran C Breen, Nathalie Gault, Liana Gross-Martirosyan, Sylvie Benchetrit, Brian Aylward, Violeta Stoyanova-Beninska, Maura O'Donovan, Sabine Straus, Jesper Kjaer, Peter Arlett
Real-World Evidence to Support EU Regulatory Decision Making-Results From a Pilot of Regulatory Use Cases. Clinical pharmacology and therapeutics (2024)
Rosa Gonzalez-Quevedo, Laura Pioppo, Juan Garcia Burgos, Peter Arlett
European Medicines Agency seeks stakeholders' views on future transparency measures for clinical trials. British journal of clinical pharmacology (2023)
Peter Arlett
Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance. Drug safety 42 (5) (2020)
Jane Moseley, Spiros Vamvakas, Michael Berntgen, Alison Cave, Xavier Kurz, Peter Arlett, Virginia Acha, Simon Bennett, Catherine Cohet, Solange Corriol-Rohou, Emma Du Four, Christelle Lamoril, Anja Langeneckert, Maren Koban, Muriel Pasté, Susan Sandler, Karin Van Baelen, Agnese Cangini, Sonia García, Mercè Obach, Emmanuel Gimenez Garcia, Leonor Varela Lema, Hanna-Mari Jauhonen, Piia Rannanheimo, Deborah Morrison, Marc Van De Casteele, Anna Strömgren, Anders Viberg, Amr Makady, Chantal Guilhaume
Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines. British journal of clinical pharmacology 86 (6) (2020)
Peter Arlett, Xavier Kurz, Katherine Soltys, Michael D Blum
International Collaboration in Real-World Evidence Generation for Direct Acting Oral Anti-Coagulants. Clinical pharmacology and therapeutics 109 (2) (2020)
Andrej Segec, Jim Slattery, Daniel R Morales, Justina Januskiene, Xavier Kurz, Peter Arlett
Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data. Pharmacoepidemiology and drug safety 30 (3) (2020)
Robert W V Flynn, Karin Hedenmalm, Tarita Murray-Thomas, Alexandra C Pacurariu, Peter Arlett, Hilary Shepherd, Puja Myles, Xavier Kurz
Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee. Clinical pharmacology and therapeutics 107 (4) (2020)
Peter Arlett
Measuring the impact of risk communications: Robust analytical approaches are key. British journal of clinical pharmacology 86 (4) (2020)
Jacoline C Bouvy, Kevin Blake, Jim Slattery, Marie Louise De Bruin, Peter Arlett, Xavier Kurz
Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013. Pharmacoepidemiology and drug safety 26 (12) (2017)